Bristol-Myers Squibb
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 8 in the most recent period (2026/Q4).
- Total institutional ownership fell 0.1 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 83.65% -0.12pp
- Institutions
- 3,023 -8
- As of
- 2026/Q4 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 33 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Sandra Leung | Former Executive Vice President | 0.02% |
| David Elkins | Chief Financial Officer | 0.01% |
| Christopher Boerner | Chairperson & CEO | 0.01% |
| Theodore Samuels | Lead Independent Director | 0.00% |
| Greg Meyers | Executive VP and Chief Digital & Technology Officer | 0.00% |
| Adam Lenkowsky | Executive VP & Chief Commercialization Officer | 0.00% |
| Samit Hirawat | Former Executive VP, Chief Medical Officer & Head of Development | 0.00% |
| Karin Shanahan | Executive VP, Chief Supply Chain & Operations Officer | 0.00% |
| Julia Haller | Independent Director | 0.00% |
| Robert Plenge | Executive VP & Chief Research Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-04 | Julia Haller | Independent Director | Open Market Disposition | -3,800 | $63.31 |
| 2026-11-02 | Adam Lenkowsky | Executive VP & Chief Commercialization Officer | Derivative Exercise and Sale | -3,848 | $61.71 |
| 2026-11-02 | Adam Lenkowsky | Executive VP & Chief Commercialization Officer | Derivative Exercise and Retained | +3,674 | -- |
| 2026-10-31 | Christopher Boerner | Chairperson & CEO | Sale to Issuer | -1,724 | $62.48 |
| 2026-10-31 | Christopher Boerner | Chairperson & CEO | Other Acquisition | +406 | -- |
| 2026-10-31 | Christopher Boerner | Chairperson & CEO | Derivative Exercise and Retained | +2,964 | -- |
| 2026-10-31 | Greg Meyers | Executive VP and Chief Digital & Technology Officer | Derivative Exercise and Sale | -2,665 | $62.48 |
| 2026-10-31 | Greg Meyers | Executive VP and Chief Digital & Technology Officer | Derivative Exercise and Retained | +3,616 | -- |
| 2026-10-31 | Karin Shanahan | Executive VP, Chief Supply Chain & Operations Officer | Derivative Exercise and Sale | -3,213 | $62.48 |
| 2026-10-31 | Karin Shanahan | Executive VP, Chief Supply Chain & Operations Officer | Derivative Exercise and Retained | +3,068 | -- |
| 2026-10-01 | Cari Gallman | Executive VP, General Counsel & Chief Policy Officer | Derivative Exercise and Sale | -2,332 | $61.15 |
| 2026-10-01 | Cari Gallman | Executive VP, General Counsel & Chief Policy Officer | Derivative Exercise and Retained | +2,227 | -- |
| 2026-09-29 | Derica Rice | Independent Director | Other Derivative Acquisition | +620 | -- |
| 2026-09-29 | Phyllis Yale | Independent Director | Other Derivative Acquisition | +560 | -- |
| 2026-09-29 | Peter Arduini | Independent Director | Other Derivative Acquisition | +560 | -- |
| 2026-09-29 | Theodore Samuels | Lead Independent Director | Other Derivative Acquisition | +821 | -- |
| 2026-09-29 | Michael McMullen | Independent director | Other Derivative Acquisition | +560 | -- |
| 2026-09-08 | Cristian Massacesi | Executive VP, Chief Medical Officer & Head of Development | Open Market Disposition | -6,249 | $64.57 |
| 2026-08-31 | Wendy Bartie | Executive VP & Chief Corporate Affairs Officer | Derivative Exercise and Sale | -633 | $66.92 |
| 2026-08-31 | Wendy Bartie | Executive VP & Chief Corporate Affairs Officer | Derivative Exercise and Retained | +603 | $66.92 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.
Bristol-Myers Squibb discussion 0 comments